When Rigel Pharma bought olutasidenib from Forma Therapeutics, it acquired a drug that already secured a PDUFA date at the ...
In a big week for Carrick Therapeutics, the company announced $60 million in funding for its lead breast cancer drug and ...
With the market cap on Horizon Therapeutics $HZNP pushed up to the $23 billion mark today, one of the Big Pharmas in the hunt ...
Gilead pulled a win last week in its ongoing patent battle with the CDC over the HIV drug Truvada for pre-exposure ...
Is 2023 finally the year for artificial intelligence to go prime time in biopharma? That’s the prediction, along with a slate ...
Pfizer and Roivant are teaming up to launch a new ‘Vant’ aimed at bringing a mid-stage anti-inflammatory drug to market, the ...
Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product ...
Gene editing company Intellia and eye disease company Iveric Bio announced that they had each raised $300 million by selling off some of their stocks. The two biotechs are the latest to raise money ...
The manufacturer of the “Doggybone DNA” synthetic vector has netted deals with big names, the latest of which is a grant from the Bill & Melinda Gates Foundation to help further Touchlight’s ...
With the US staring down several drug shortages this year, one in particular is now catching lawmakers' attention. A bipartisan group of senators sent a letter to HHS Secretary Xavier Becerra and FDA ...
The Institute for Clinical and Economic Review (ICER) on Thursday published a new evidence report for Astellas Pharma's fezolinetant, recommending that the potential oral, nonhormonal drug designed to ...
ViiV Healthcare is pulling together an eclectic coalition of consumer businesses in a new White House-endorsed effort to end HIV by the end of the decade. The new US Business Action to End HIV ...